

References

Z-75

1. Vecchioli-Scaldazza C, Morosetti C, Giampieretti R, et al. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: Results of a randomized controlled study. *Int Braz J Urol.* 2017;43(1):121-126.
2. Simillis C, Lal N, Qiu S, et al. Sacral nerve stimulation versus percutaneous tibial nerve stimulation for faecal incontinence: A systematic review and meta-analysis. *International J Colorectal Dis.* 2018;33(5):645-8.
3. Sanagapalli S, Neilan L, Lo JYT, et al. Efficacy of percutaneous posterior tibial nerve stimulation for the management of fecal incontinence in multiple sclerosis: A pilot study. 2018;21(7):682-7.
4. Hayes, Inc. Comparative Effectiveness Review. Comparative Effectiveness Review of Percutaneous Tibial Nerve Stimulation for the Treatment of Symptomatic Non-Neurogenic Overactive Bladder. Lansdale, PA: Hayes, Inc.; 02/04/2020.
5. Hayes, Inc. Medical Technology Directory. Percutaneous Tibial Nerve Stimulation for the Treatment of Symptomatic Neurogenic Lower Urinary Tract Dysfunction. Lansdale, Pa: Hayes, Inc.; 04/15/2019.
6. Tutolo M, Ammirati E, Heesakkers J, et al. Efficacy and safety of sacral and percutaneous tibial neuromodulation in non-neurogenic lower urinary tract dysfunction and chronic pelvic pain: A systematic review of the literature. *Eur Urol.* 2018;73(3):406-418.
7. Tutolo M, Ammirati E, Van der Aa F. What is new in neuromodulation for overactive bladder? *Eur Urol Focus.* 2018;4(1):49-53.
8. Sarveazad A, Babahajian A, Amini N, et al. Posterior tibial nerve stimulation in fecal incontinence: A systematic review and meta-analysis. *Basic Clin Neurosci.* 2019;10(5):419-431.
9. Tan K, Wells CI, Dinning P, et al. Placebo response rates in electrical nerve stimulation trials for fecal incontinence and constipation: A systematic review and meta-analysis. 2020;23(8):1108-1116.
10. Bharucha AE, Rao SSC, Shin AS. Surgical interventions and the use of device-aided therapy for the treatment of fecal incontinence and defecatory disorders. *Clin Gastroenterol Hepatol.* 2017;15(12):1844-1854.
11. Kavanagh A, Baverstock R, Campeau L, et al. Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction. *Can Urol Assoc J.* 2019;13(6):E157-E176.
12. Rahnama'i MS. Neuromodulation for functional bladder disorders in patients with multiple sclerosis. *Mult Scler.* 2020;26(11):1274-1280.
13. Lane GI, Mao-Draayer Y, Barboglio-Romo P, et al. A prospective observational cohort study of posterior tibial nerve stimulation in patients with multiple sclerosis: Design and methods. *BMC Urol.* 2020;20(1):58.
14. Canbaz Kabay S, Kabay S, Mestan E, et al. Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results. *Neurol Urodyn.* 2017;36(1):104-110.

15. Tudor KI, Seth JH, Liechti MD, et al. Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder. *Clin Auton Res.* 2020;30(1):61-67.
16. Andersen K, Kobberø H, Pedersen TB, Poulsen MH. Percutaneous tibial nerve stimulation for idiopathic and neurogenic overactive bladder dysfunction: A four-year follow-up single-centre experience. *Scand J Urol.* 2021;55(2):169-176.
17. Wang M, Jian Z, Ma Y, Jin X, Li H, Wang K. Percutaneous tibial nerve stimulation for overactive bladder syndrome: A systematic review and meta-analysis. *Int Urogynecol J.* 2020;31(12):2457-2471.
18. Xiong SC, Peng L, Hu X, Shao YX, Wu K, Li X. Effectiveness and safety of tibial nerve stimulation versus anticholinergic drugs for the treatment of overactive bladder syndrome: A meta-analysis. *Ann Palliat Med.* 2021;10(6):6287-6296.
19. Horrocks EJ, Chadi SA, Stevens NJ, Wexner SD, Knowles CH. Factors associated with efficacy of percutaneous tibial nerve stimulation for fecal incontinence, based on post-hoc analysis of data from a randomized trial. *Clin Gastroenterol Hepatol.* 2017;15(12):1915-1921.e2.
20. Lo CW, Wu MY, Yang SS, Jaw FS, Chang SJ. Comparing the efficacy of OnabotulinumtoxinA, sacral neuromodulation, and peripheral tibial nerve stimulation as third line treatment for the management of overactive bladder symptoms in adults: Systematic review and network meta-analysis. *Toxins (Basel).* 2020 Feb 18;12(2):128.
21. Lashin AM, Eltabey NA, Wadie BS. Percutaneous tibial nerve stimulation versus sham efficacy in the treatment of refractory overactive bladder: Outcomes following a shortened 6-week protocol, a prospective randomized controlled trial. *Int Urol Nephrol.* 2021;53(12):2459-2467.
22. Vollstedt A, Gilleran J. Update on implantable PTNS devices. *Curr Urol Rep.* 2020;21(7):28.
23. Yamashiro J, de Riese W, de Riese C. New implantable tibial nerve stimulation devices: Review of published clinical results in comparison to established neuromodulation devices. *Res Rep Urol.* 2019;11:351-357.
24. Rahnema'i MS. Neuromodulation for functional bladder disorders in patients with multiple sclerosis. *Mult Scler.* 2020;26(11):1274-1280.
25. Janssen DA, Martens FM, de Wall LL, van Breda HM, Heesakkers JP. Clinical utility of neurostimulation devices in the treatment of overactive bladder: Current perspectives. *Med Devices (Auckl).* 2017;10:109-122.
26. Te Dorsthorst M, Digesu A, van Kerrebroeck P, et al. Patient-tailored healthcare and tibial nerve neuromodulation in the treatment of patients with overactive bladder symptoms. *Neurourol Urodyn.*